Skip to main content
. 2017 Nov 30;23(5):631–636. doi: 10.1634/theoncologist.2017-0301

Table 1. Summary of key favorable and unfavorable effects (Study D2308).

image

a

Subgroup of patients who received at least two prior regimens including bortezomib and an immunomodulating agent.

b

FAS population.

Abbreviations: BTZ, bortezomib; Dex, dexamethasone; FAS, full analysis set; HR, hazard ratio; OS, overall survival; PFS, progression‐free survival; PAN, panobinostat.